Evidence map›Paper›PMID 28975094›Full record

ArticleJournal of nephropathology2017

Ameliorative effect of lycopene effect on cisplatin-induced nephropathy in patient.

Leila Mahmoodnia, Keivan Mohammadi, Rohollah Masumi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nephropathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 3 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Cisplatin chemotherapy and renal function.Advances in cancer research · 2021
    Review
  11. Article
  12. Review
  13. New insight into the effect of lycopene on the oxidative stress in acute kidney injury.International journal of critical illness and injury science · 2020
    Article
  14. Review
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Leila MahmoodniaDepartment of Internal Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Keivan MohammadiDepartment of Internal Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Rohollah MasumiDepartment of Internal Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Shahrekord University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNephrotoxicity is one of the most important limitations of cisplatin-based chemotherapies which associated with many complications and high mortality rate.

objectivesTo investigate the effect of lycopene on cisplatin-induced nephrotoxicity in patients with cancer. PATIENTS AND

methodsIn this double-blind, randomized clinical trial, 120 patients were randomly assigned to two groups, case (treated with lycopene + standard regimen of kidney injury prevention) and control (treated with only the standard regimen of kidney injury prevention). Lycopene was orally taken from 24 hours before to 72 hours after cisplatin administration. Blood urea nitrogen (BUN), serum creatinine (Cr), and glomerular filtration rate (GFR) were measured and recorded. The data were analyzed using SPSS.

resultsChanges in Cr were not significantly different between the two groups (P = 0.131). However, a significant decreasing trend was seen in GFR during the study, which was more marked in the control group (P = 0.004). BUN significantly decreased during the study (P = 0.002), and a significant decrease of BUN on the day three in both groups was seen (P = 0.001). However, BUN increased in the case group on the day 21 of treatment. The corresponding increase was less marked in the control group.

conclusionsLycopene can be considered a useful adjuvant therapy to decrease the complications due to cisplatin-induced nephrotoxicity in patients with cancer.

Indexed as

CancerCisplatinLycopeneNephrotoxicity

Identifiers

PMID28975094
PMCPMC5607975
OpenAlexW2615578443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.